Seagen Touts Adcetris Early-Stage Lymphoma Data with 93% Complete Remission

Tuesday, Seagen announced results from part C of its three-part Phase II trial in early-stage classical Hodgkin lymphoma, reporting that Adcetris (brentuximab vedotin) used in a combination approach led to complete remission in 93% of 150 patients.